Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Acurx says FDA conditionally accepts CIFBEZY brand name for ibezapolstat

Acurx says FDA conditionally accepts CIFBEZY brand name for ibezapolstat

ReutersReuters2026/08/17 12:03
  • Acurx won FDA conditional acceptance for CIFBEZY as the proposed brand name for its lead antibiotic candidate ibezapolstat.
  • USPTO allowed the CIFBEZY trademark application, supporting future commercialization plans tied to a potential NDA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608170801PR_NEWS_USPR_____NY27012) on August 17, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AstraZeneca (AZN.US) Relizumab's third indication approved for marketing in China

Rituximab was first approved for use in China in April 2025, and this is the third approved indication for the drug in the country.

智通财经2026/08/20 09:01
AstraZeneca (AZN.US) Relizumab's third indication approved for marketing in China